Top

Breast Cancer Research and Treatment

Published in:

01-12-2020 | Breast Cancer | Epidemiology

Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer

Authors: Yunan Han, Zhi-Feng Miao, Min Lian, Lindsay L. Peterson, Graham A. Colditz, Ying Liu

Published in: Breast Cancer Research and Treatment | Issue 3/2020

Abstract

Purpose

Cutoffs of the 21-gene recurrence score (RS), a commonly used genomic assay for hormone receptor-positive breast cancer, have been updated. Little is known about racial/ethnic differences in RS results, RS-guided chemotherapy use, and outcomes on updated cutoff (RS ≥ 31 defined as high-risk) in the real-world setting.

Methods

A total of 81,937 women [75.0% whites, 7.7% blacks, 8.3% Asian American/Pacific Islanders (AAPIs), and 9.0% Hispanics] diagnosed with hormone receptor-positive breast cancer between 2004 and 2015, who received the 21-gene assay, were identified from the Surveillance, Epidemiology, and End Results. Logistic regressions estimated the race-associated odds ratios (ORs) of RS and chemotherapy use. Cox regressions estimated the race-associated hazard ratios (HRs) of breast cancer-specific and all-cause mortality.

Results

Compared with white women, black women were more likely to have RS-defined high-risk tumors (adjusted OR [aOR] 1.29; 95% CI 1.16–1.42). In high RS, blacks had lower odds of chemotherapy use (aOR 0.76; 95% CI 0.62–0.94) than whites, particularly among women ≥ 65 years (aOR 0.51; 95% CI 0.35–0.76), while AAPI and Hispanic women had no variation in chemotherapy use compared with whites in high RS. Black women had a higher risk of breast cancer-specific mortality (HR 1.37; 95% CI 1.12–1.67) and all-cause mortality compared with white women after adjusting for demographic and pathological factors, county-level socioeconomic deprivation, treatments and RS; AAPIs had lower mortality and Hispanics had similar mortality.

Conclusions

Black women were more likely to have a high-risk RS tumor and less likely to receive chemotherapy in the group of high RS, especially those ≥ 65 years. Further studies are needed to identify barriers to chemotherapy in black patients with high RS scores.

Available only for authorised users

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492CrossRefPubMed

American Cancer Society (2017) Breast cancer facts & figures 2017–2018. American Cancer Society Inc, Atlanta

Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, Cronin KA (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. https://doi.org/10.1093/jnci/dju055CrossRefPubMedPubMedCentral

Warner ET, Tamimi RM, Hughes ME, Ottesen RA, Wong YN, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Partridge AH (2015) Racial and ethnic differences in breast cancer survival: mediating effect of tumor characteristics and sociodemographic and treatment factors. J Clin Oncol 33(20):2254–2261. https://doi.org/10.1200/jco.2014.57.1349CrossRefPubMedPubMedCentral

O'Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, Dressler LG, Geradts J, Millikan RC (2010) Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 16(24):6100–6110. https://doi.org/10.1158/1078-0432.ccr-10-1533CrossRefPubMedPubMedCentral

Anderson WF, Rosenberg PS, Menashe I, Mitani A, Pfeiffer RM (2008) Age-related crossover in breast cancer incidence rates between black and white ethnic groups. J Natl Cancer Inst 100(24):1804–1814. https://doi.org/10.1093/jnci/djn411CrossRefPubMedPubMedCentral

Hershman DL, Unger JM, Barlow WE, Hutchins LF, Martino S, Osborne CK, Livingston RB, Albain KS (2009) Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. J Clin Oncol 27(13):2157–2162. https://doi.org/10.1200/jco.2008.19.1163CrossRefPubMedPubMedCentral

Bickell NA, Wang JJ, Oluwole S, Schrag D, Godfrey H, Hiotis K, Mendez J, Guth AA (2006) Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol 24(9):1357–1362. https://doi.org/10.1200/jco.2005.04.5799CrossRefPubMed

Menashe I, Anderson WF, Jatoi I, Rosenberg PS (2009) Underlying causes of the black-white racial disparity in breast cancer mortality: a population-based analysis. J Natl Cancer Inst 101(14):993–1000. https://doi.org/10.1093/jnci/djp176CrossRefPubMedPubMedCentral

10.

Troester MA, Sun X, Allott EH, Geradts J, Cohen SM, Tse CK, Kirk EL, Thorne LB, Mathews M, Li Y, Hu Z, Robinson WR, Hoadley KA, Olopade OI, Reeder-Hayes KE, Earp HS, Olshan AF, Carey LA, Perou CM (2018) Racial differences in PAM50 subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djx135CrossRefPubMed

11.

Petkov VI, Miller DP, Howlader N, Gliner N, Howe W, Schussler N, Cronin K, Baehner FL, Cress R, Deapen D, Glaser SL, Hernandez BY, Lynch CF, Mueller L, Schwartz AG, Schwartz SM, Stroup A, Sweeney C, Tucker TC, Ward KC, Wiggins C, Wu XC, Penberthy L, Shak S (2016) Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. NPJ Breast Cancer 2:16017. https://doi.org/10.1038/npjbcancer.2016.17CrossRefPubMedPubMedCentral

12.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826. https://doi.org/10.1056/NEJMoa041588CrossRefPubMed

13.

Kwa M, Makris A, Esteva FJ (2017) Clinical utility of gene-expression signatures in early stage breast cancer. Nat Rev Clin Oncol 14(10):595–610. https://doi.org/10.1038/nrclinonc.2017.74CrossRefPubMed

14.

Geyer CE Jr, Tang G, Mamounas EP, Rastogi P, Paik S, Shak S, Baehner FL, Crager M, Wickerham DL, Costantino JP, Wolmark N (2018) 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer. NPJ Breast Cancer 4:37. https://doi.org/10.1038/s41523-018-0090-6CrossRefPubMedPubMedCentral

15.

Mamounas EP, Russell CA, Lau A, Turner MP, Albain KS (2018) Clinical relevance of the 21-gene recurrence score((R)) assay in treatment decisions for patients with node-positive breast cancer in the genomic era. NPJ Breast Cancer 4:27. https://doi.org/10.1038/s41523-018-0082-6CrossRefPubMedPubMedCentral

16.

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24(23):3726–3734. https://doi.org/10.1200/jco.2005.04.7985CrossRefPubMed

17.

Dowsett M, Cuzick J, Wale C, Forbes J, Mallon EA, Salter J, Quinn E, Dunbier A, Baum M, Buzdar A, Howell A, Bugarini R, Baehner FL, Shak S (2010) Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 28(11):1829–1834. https://doi.org/10.1200/jco.2009.24.4798CrossRefPubMed

18.

Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11(1):55–65. https://doi.org/10.1016/s1470-2045(09)70314-6CrossRefPubMed

19.

Paik S (2007) Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist 12(6):631–635. https://doi.org/10.1634/theoncologist.12-6-631CrossRefPubMed

20.

Massarweh SA, Sledge GW, Miller DP, McCullough D, Petkov VI, Shak S (2018) Molecular characterization and mortality from breast cancer in men. J Clin Oncol 36(14):1396–1404. https://doi.org/10.1200/jco.2017.76.8861CrossRefPubMedPubMedCentral

21.

National Comprehensive Cancer Network (2019) Breast cancer (version 1. 2019). National Comprehensive Cancer Network, Plymouth Meeting

22.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr (2018) Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 379(2):111–121. https://doi.org/10.1056/NEJMoa1804710CrossRefPubMedPubMedCentral

23.

Albain K, Gray R, Sparano J, Makower D, Pritchard K, Hayes D, Geyer C, Dees E, Goetz M, Olson J, Lively T, Badve S, Saphner T, Wagner L, Whelan T, Ellis M, Paik S, Wood W, Ravdin P, Keane M, Gomez H, Reddy P, Goggins T, Mayer I, Brufsky A, Toppmeyer D, Kaklamani V, Berenberg J, Abrams J, Sledge G (2019) Abstract GS4–07: Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer: results from the TAILORx trial. Cancer Res. https://doi.org/10.1158/1538-7445.sabcs18-gs4-07CrossRefPubMedPubMedCentral

24.

National Cancer Institute (2019) Surveillance, epidemiology, and end results program. SEER incidence data, 1975–2016. National Cancer Institute, Bethesda

25.

National Cancer Institute. Surveillance, Epidemiology, and End Results program.Oncotype DX Database (2004–2015).

26.

National Cancer Institute (2019) Surveillance, epidemiology, and end results program. Rural-urban continuum codes. https://seer.cancer.gov/seerstat/variables/countyattribs/ruralurban.html. Accessed 12 June 2019

27.

Lian M, Struthers J, Liu Y (2016) Statistical assessment of neighborhood socioeconomic deprivation environment in spatial epidemiologic studies. Open J Stat 6:436–442CrossRefPubMedPubMedCentral

28.

Lian M, Perez M, Liu Y et al (2014) Neighborhood socioeconomic deprivation, tumor subtypes, and causes of death after non-metastatic invasive breast cancer diagnosis: a multilevel competing-risk analysis. Breast Cancer Res Treat 147:661–670CrossRefPubMedPubMedCentral

29.

Zhang S, Liu Y, Yun S et al (2018) Impacts of neighborhood characteristics on treatment and outcomes in women with ductal carcinoma in situ of the breast. Cancer Epidemiol Biomark Prev 27:1298–1306CrossRef

30.

Lin DY, Wei LJ, Ying Z (1993) Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika 80(3):557–572. https://doi.org/10.1093/biomet/80.3.557CrossRef

31.

Holowatyj AN, Cote ML, Ruterbusch JJ, Ghanem K, Schwartz AG, Vigneau FD, Gorski DH, Purrington KS (2018) Racial differences in 21-gene recurrence scores among patients with hormone receptor-positive, node-negative breast cancer. J Clin Oncol 36(7):652–658. https://doi.org/10.1200/jco.2017.74.5448CrossRefPubMedPubMedCentral

32.

Lund MJ, Mosunjac M, Davis KM, Gabram-Mendola S, Rizzo M, Bumpers HL, Hearn S, Zelnak A, Styblo T, O'Regan RM (2012) 21-Gene recurrence scores: racial differences in testing, scores, treatment, and outcome. Cancer 118(3):788–796. https://doi.org/10.1002/cncr.26180CrossRefPubMed

33.

Jasem J, Amini A, Rabinovitch R, Borges VF, Elias A, Fisher CM, Kabos P (2016) 21-gene recurrence score assay as a predictor of adjuvant chemotherapy administration for early-stage breast cancer: an analysis of use, therapeutic implications, and disparity profile. J Clin Oncol 34(17):1995–2002. https://doi.org/10.1200/jco.2015.65.0887CrossRefPubMedPubMedCentral

34.

Osborne C, Ostir GV, Du X, Peek MK, Goodwin JS (2005) The influence of marital status on the stage at diagnosis, treatment, and survival of older women with breast cancer. Breast Cancer Res Treat 93(1):41–47. https://doi.org/10.1007/s10549-005-3702-4CrossRefPubMed

35.

Hinyard L, Wirth LS, Clancy JM, Schwartz T (2017) The effect of marital status on breast cancer-related outcomes in women under 65: a SEER database analysis. Breast (Edinburgh, Scotland) 32:13–17. https://doi.org/10.1016/j.breast.2016.12.008CrossRef

36.

Hsu CD, Wang X, Habif DV Jr, Ma CX, Johnson KJ (2017) Breast cancer stage variation and survival in association with insurance status and sociodemographic factors in US women 18 to 64 years old. Cancer 123(16):3125–3131. https://doi.org/10.1002/cncr.30722CrossRefPubMed

37.

Williams F, Thompson E (2016) Disparity in breast cancer late stage at diagnosis in missouri: does rural versus urban residence matter? J Racial Ethnic Health Disparities 3(2):233–239. https://doi.org/10.1007/s40615-015-0132-9CrossRef

38.

Nguyen-Pham S, Leung J, McLaughlin D (2014) Disparities in breast cancer stage at diagnosis in urban and rural adult women: a systematic review and meta-analysis. Ann Epidemiol 24(3):228–235. https://doi.org/10.1016/j.annepidem.2013.12.002CrossRefPubMed

39.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW (2015) Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 373(21):2005–2014. https://doi.org/10.1056/NEJMoa1510764CrossRefPubMedPubMedCentral

40.

Mamounas EP, Liu Q, Paik S, Baehner FL, Tang G, Jeong JH, Kim SR, Butler SM, Jamshidian F, Cherbavaz DB, Sing AP, Shak S, Julian TB, Lembersky BC, Wickerham DL, Costantino JP, Wolmark N (2017) 21-gene recurrence score and locoregional recurrence in node-positive/ER-positive breast cancer treated with chemo-endocrine therapy. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djw259CrossRefPubMedPubMedCentral

41.

Roberts MC, Weinberger M, Dusetzina SB, Dinan MA, Reeder-Hayes KE, Troester MA, Carey LA, Wheeler SB (2015) Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing. Breast Cancer Res Treat 153(1):191–200. https://doi.org/10.1007/s10549-015-3518-9CrossRefPubMedPubMedCentral

42.

Press DJ, Ibraheem A, Dolan ME, Goss KH, Conzen S, Huo D (2018) Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results. Breast Cancer Res Treat 168(1):207–220. https://doi.org/10.1007/s10549-017-4587-8CrossRefPubMed

43.

Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D (2005) Comorbidity and survival disparities among black and white patients with breast cancer. JAMA 294(14):1765–1772. https://doi.org/10.1001/jama.294.14.1765CrossRefPubMed

44.

Adler NE, Newman K (2002) Socioeconomic disparities in health: pathways and policies. Health Affairs (Project Hope) 21(2):60–76. https://doi.org/10.1377/hlthaff.21.2.60CrossRef

45.

Buist DS, Chubak J, Prout M, Yood MU, Bosco JL, Thwin SS, Gold HT, Owusu C, Field TS, Quinn VP, Wei F, Silliman RA (2009) Referral, receipt, and completion of chemotherapy in patients with early-stage breast cancer older than 65 years and at high risk of breast cancer recurrence. J Clin Oncol 27(27):4508–4514. https://doi.org/10.1200/jco.2008.18.3459CrossRefPubMedPubMedCentral

46.

Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE (2012) Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. J Natl Cancer Inst 104(5):406–414. https://doi.org/10.1093/jnci/djr543CrossRefPubMedPubMedCentral

47.

Enewold L, Geiger AM, Zujewski J, Harlan LC (2015) Oncotype Dx assay and breast cancer in the United States: usage and concordance with chemotherapy. Breast Cancer Res Treat 151(1):149–156. https://doi.org/10.1007/s10549-015-3366-7CrossRefPubMed

48.

Cress RD, Chen YS, Morris CR, Chew H, Kizer KW (2016) Underutilization of gene expression profiling for early-stage breast cancer in California. Cancer Causes Control CCC 27(6):721–727. https://doi.org/10.1007/s10552-016-0743-4CrossRefPubMedPubMedCentral

49.

Farias AJ, Du XL (2017) Racial differences in adjuvant endocrine therapy use and discontinuation in association with mortality among medicare breast cancer patients by receptor status. Cancer Epidemiol Biomark Prev 26(8):1266–1275. https://doi.org/10.1158/1055-9965.epi-17-0280CrossRef

50.

Farias AJ, Du XL (2017) Association between out-of-pocket costs, race/ethnicity, and adjuvant endocrine therapy adherence among medicare patients with breast cancer. J Clin Oncol 35(1):86–95. https://doi.org/10.1200/jco.2016.68.2807CrossRefPubMed

Title: Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer
Authors: Yunan Han
Zhi-Feng Miao
Min Lian
Lindsay L. Peterson
Graham A. Colditz
Ying Liu
Publication date: 01-12-2020
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Cytostatic Therapy
Published in: Breast Cancer Research and Treatment / Issue 3/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05902-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2020

Language impairment among patients with different types of cancer. Comparison with healthy adults

Treatment interruption and discontinuation of hormonal therapy in hormone receptor-positive breast cancer patients

Screening women at high risk for breast cancer: one program fits all?

Luminal subtypes and response to neoadjuvant chemotherapy for hormone receptor-positive HER2-negative patients

Acknowledgement of reviewers 2019

Clinical performance of contrast-enhanced spectral mammography in pre-surgical evaluation of breast malignant lesions in dense breasts: a single center study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer